Japan Drug Delivery Devices Market Insight
Published: 12 June 2026 | Report Format: Electronic (PDF)
The Japan drug delivery devices market is expected to grow at a CAGR of 8.44% owing to an ageing population, rising chronic diseases, increasing self-administration preference, smart device adoption, and government support for advanced drug-device products.
Japan Drug Delivery Devices Market Insights Forecasts to 2035
- The Japan Drug Delivery Devices Market Size Was Estimated USD 13.04 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 8.44% from 2026 to 2031
- The Japan Drug Delivery Devices Market Size is Expected to rise around USD 21.22 Billion by 2031
Notable Insights for the Japan Drug Delivery Devices Market
- The device-type segmentation indicates that the Injectable Drug Delivery Devices segment holds a commanding position with almost 43% market share in the Japan Drug Delivery Devices Market in 2025 due to its extensive use in managing chronic conditions such as diabetes, oncology, and autoimmune diseases, along with growing adoption of ergonomic autoinjectors and prefilled syringe systems.
- The route of administration-based segmentation shows that the Injectable Route dominates with a market share of almost 56% in the Japan Drug Delivery Devices Market in 2025 as a result of the entrenched role of biologics delivery, biologic drug approvals, and a nationwide shift toward home-based self-injection care models.
- Terumo Corporation, Japan's leading domestic medical technology firm, reported FY 2025 revenue of approximately JPY 1,036.2 billion (USD 6.9 billion), underpinned by strong demand for injectable delivery systems, prefilled syringes, and drug-device combination products across domestic and global markets.
- As per expectations, AI-driven smart device integration, biodegradable implantable formats, and government fast-track pathways for Software as a Medical Device (SaMD) will drive market expansion in which smart connected drug delivery devices improve medication adherence rates by up to 38% and reduce hospital readmission rates by up to 25%.
Download the eBook (ToC)
Research Methodologies Used to Analyze the Japan Drug Delivery Devices Market
The Japan drug delivery devices market is analyzed through a blend of primary and secondary research approaches for ensuring accurate information about the market and its forecasted performance. Primary research is conducted through discussions with medical device manufacturers and distributors, hospital procurement teams, pharmaceutical companies, regulatory consultants, and healthcare professionals to evaluate demand trends, technological advancements, and competitive strategies. Secondary research involves analyzing reports published by companies and government health agencies, clinical journals, medical device regulatory filings, import-export databases, and industry organizations related to the healthcare and pharmaceutical sectors. Market estimation, trend analysis, and forecasting techniques are applied to determine market size, growth opportunities, pricing dynamics, and investment activity across Japan's evolving drug delivery devices landscape.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Drug Delivery Devices Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Drug Delivery Devices Market
- Terumo Corporation
- Nipro Corporation
- Becton, Dickinson and Company (BD)
- Johnson & Johnson (Janssen)
- Omron Healthcare Co., Ltd.
- Taisei Kako Co., Ltd.
- GlaxoSmithKline Plc (Japan)
- Novartis AG (Japan)
- Bayer AG (Japan)
- 3M Company (Japan)
Recent Developments:
- In June 2025, Aerogen, the Ireland-based global leader in acute-care aerosol drug delivery, announced new expansion and investment plans for its operations in Japan to advance respiratory care and improve access to cutting-edge aerosol delivery solutions for patients with COPD, asthma, and other chronic respiratory conditions.
- In April 2024, Nipro Corporation and Haselmeier announced an exclusive strategic partnership to promote and distribute the PiccoJect next-generation two-step autoinjector platform in Japan, with commercial availability confirmed from Q1 2025, targeting pharmaceutical and biotechnology companies requiring compact subcutaneous drug delivery solutions.
Market Segmentation:
Japan Drug Delivery Devices Market, By Device Type
- Injectable Drug Delivery Devices
- Inhalation Drug Delivery Devices
- Topical & Transdermal Drug Delivery Devices
- Implantable Drug Delivery Systems
- Ocular & Oral Drug Delivery Devices
Japan Drug Delivery Devices Market, By Technology
- Conventional Mechanical Drug Delivery Systems
- Electronic & Smart Connected Delivery Platforms
- AI-Driven Dosage Management Systems
- Biodegradable & Controlled-Release Implant Technologies
- Wearable & Patch-Based Delivery Innovations
Japan Drug Delivery Devices Market, By Application
- Diabetes Management
- Oncology & Cancer Therapeutics
- Cardiovascular Disease
- Respiratory & Pulmonary Conditions
- Infectious Diseases & Immunology
Expert Views:
The growth of drug delivery devices markets in Japan will be facilitated by increased adoption of advanced injectable and self-administration systems, growing numbers of elderly patients managing chronic conditions, and stronger demand for patient-friendly formats that support home-based care. The integration of AI-driven smart injection platforms, wearable drug delivery technologies, and biodegradable implantable systems will contribute to improved treatment adherence, enhanced patient outcomes, and expanded demand across diabetes management, oncology treatment, cardiovascular care, respiratory therapy, and infectious disease management markets in Japan.
Author: Govind and Krishna By Decisions Advisors and Consulting